Retinoblastoma (RB) is the most common intraocular cancer in children worldwide. Current treatments mainly involve combinations of chemotherapies, cryotherapies, and laser-based therapies. Severe or late-stage disease may require enucleation or lead to fatality. Recently, RB has been shown to arise from cone precursor cells, which have high MDM2 levels to suppress p53-mediated apoptosis. This finding leads to the hypothesis that restoring apoptosis mechanisms in RBs could specifically kill the cancer cells without affecting other retinal cells. We have previously reported involvement of an extrapituitary signaling pathway of the growth hormone-releasing hormone (GHRH) in the retina. Here we show that the GHRH receptor (GHRH-R) is highly expressed in RB cells but not in other retinal cells. We induced specific apoptosis with two different GHRH-R antagonists, MIA-602 and MIA-690. Importantly, these GHRH-R antagonists do not trigger apoptosis in other retinal cells such as retinal pigmented epithelial cells. We delineated the gene expression profiles regulated by GHRH-R antagonists and found that cell proliferation genes and apoptotic genes are down- and up-regulated, respectively. Our results reveal the involvement of GHRH-R in survival and proliferation of RB and demonstrate that GHRH-R antagonists can specifically kill the RB cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167144PMC
http://dx.doi.org/10.1073/pnas.1617427113DOI Listing

Publication Analysis

Top Keywords

ghrh-r antagonists
16
cells retinal
12
retinal cells
12
cells
9
growth hormone-releasing
8
hormone-releasing hormone
8
ghrh-r
6
antagonists
5
apoptosis
5
antagonists growth
4

Similar Publications

Effects of GHRH and its analogues on the Vascular System.

Rev Endocr Metab Disord

November 2024

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China.

Article Synopsis
  • - GHRH (Growth hormone-releasing hormone) is an important hormone that activates specific receptors (GHRH-R) on cells, triggering various signaling pathways and promoting growth hormone release from the pituitary gland.
  • - Besides influencing growth hormone secretion, GHRH also helps in maintaining overall body balance by interacting with different tissues that have GHRH-R.
  • - Recent research has highlighted the role of GHRH and its synthetic analogues in blood vessel interactions, notably in promoting the formation of new blood vessels (angiogenesis) and reducing vascular calcification.
View Article and Find Full Text PDF

GHRH and the prostate.

Rev Endocr Metab Disord

November 2024

Departamento de Biología de Sistemas. Unidad de Bioquímica y Biología Molecular (Research group "Cánceres de origen epitelial"), Universidad de Alcalá, Campus Científico-Tecnológico, 28871, Alcalá de Henares, Madrid, Spain.

Article Synopsis
  • In the late 1960s and early 1970s, researchers isolated and studied hypothalamic regulatory hormones, discovering both normal and tumor tissues can produce growth hormone-releasing hormone (GHRH).
  • GHRH receptors, particularly the pituitary-type (pGHRH-R), are predominantly found in the anterior pituitary but also in other body cells and various cancers, including prostate cancer, with splice variants detected in these tissues.
  • GHRH activates multiple signaling pathways that promote cell survival and proliferation, making GHRH receptors potential drug targets, especially in prostate conditions, with recent antagonists showing enhanced anticancer and anti-inflammatory effects.
View Article and Find Full Text PDF

GHRH and its analogues in central nervous system diseases.

Rev Endocr Metab Disord

October 2024

Science and Experiment Research Center & Shenyang Key Laboratory of Vascular Biology, Shenyang Medical College, Shenyang, 110034, China.

Growth hormone-releasing hormone (GHRH) is primarily produced by the hypothalamus and stimulates the release of growth hormone (GH) in the anterior pituitary gland, which subsequently regulates the production of hepatic insulin-like growth factor-1 (IGF-1). GH and IGF-1 have potent effects on promoting cell proliferation, inhibiting cell apoptosis, as well as regulating cell metabolism. In central nerve system (CNS), GHRH/GH/IGF-1 promote brain development and growth, stimulate neuronal proliferation, and regulate neurotransmitter release, thereby participating in the regulation of various CNS physiological activities.

View Article and Find Full Text PDF

Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.

Int J Mol Sci

October 2024

Grupo de Investigación Cánceres de Origen Epitelial, Departamento de Biología de Sistemas, Campus Científico-Tecnológico, Universidad de Alcalá, 28805 Madrid, Spain.

Article Synopsis
  • The study investigates the combined effects of GHRH-R antagonist MIA-690 and EGFR inhibitor Gefitinib on advanced prostate cancer cells, as treating castration-resistant prostate cancer (CRPC) is challenging due to drug resistance.
  • Findings show that this combination therapy significantly reduces cell viability, adhesion, and metalloprotease activity, while also causing cell cycle arrest in prostate cancer PC-3 cells.
  • In vivo results from athymic nude mice confirm that the combined treatment is more effective against tumors than using either drug alone, by disrupting the interaction between GHRH-R and EGFR pathways.
View Article and Find Full Text PDF

Growth hormone-releasing hormone and cancer.

Rev Endocr Metab Disord

October 2024

Department of Medical Sciences, University of Turin, Turin, Italy.

The hypothalamic hormone growth hormone-releasing hormone (GHRH), in addition to promoting the synthesis and release of growth hormone (GH), stimulates the proliferation of human normal and malignant cells by binding to GHRH-receptor (GHRH-R) and its main splice variant, SV1. Both GHRH and GHRH-Rs are expressed in various cancers, forming a stimulatory pathway for cancer cell growth; additionally, SV1 possesses ligand independent proliferative effects. Therefore, targeting GHRH-Rs pharmacologically has been proposed for the treatment of cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!